Rational Design of PZM21: A Review on Novel OR Agonist Achieving Analgesia Without Traditional Opioid Side Effects

The creation of potent but safer opioid analgesics is still a daunting challenge in pain control because of the unwanted effects of conventional opioids, including respiratory depression, constipation, and addiction. This review article presents the discovery and optimization of PZM21, a new μ-opioid receptor (μOR) agonist, based on a structure-based drug design strategy. By computer-aided screening of more than three million compounds against an inactive or crystal structure, scientists discovered new chemotypes featuring novel scaffold architectures. Lead molecules were culled on the basis of critical receptor-ligand contacts and synthesized to enhance potency, selectivity, and G-protein preference. Stereochemically defined (S,S)-isomer PZM21 showed sub-nanomolar binding affinity for μOR, potent Gi/o signaling, and minimal β-arrestin-2 recruitment or receptor internalization. Functional assays and in vivo experiments validated PZM21's efficacious analgesic activity with a significantly lower side effect profile than morphine and TRV130. In particular, PZM21 had minimal respiratory depression, weak induction of constipation, and no conditioned place preference or hyperlocomotion, suggesting low abuse liability. Molecular dynamics simulations and docking experiments validated the ligand's distinctive binding pose and selectivity, further confirmed by structure-activity relationships and irreversible binding assays. PZM21's unique pharmacology highlights the value of structure-based ligand discovery in creating future opioid therapeutics that are as effective but with fewer liabilities inherent in traditional opioids.